Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.975
Bid: 2.85
Ask: 3.10
Change: 0.10 (3.48%)
Spread: 0.25 (8.772%)
Open: 2.875
High: 2.975
Low: 2.875
Prev. Close: 2.875
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Shareholder Meetings Calendar - Next 7 Days

Tue, 01st Dec 2020 16:06

Wednesday 2 December 
Kingswood Holdings LtdAGM
Target Healthcare REIT PLCAGM
JPMorgan Global Emerging Markets Income Trust PLCAGM
Gunsynd PLCGM re share placing
Rambler Metals & Mining PLCAGM
Thursday 3 December 
Nanoco Group PLCAGM
Marwyn Value Investors LtdAGM adjourned from 17 November
CQS New City High Yield Fund LtdAGM
B&M European Value Retail SAEGM re changes related to Brexit
MJ Gleeson PLCAGM
Ormonde Mining PLCAGM
Ferguson PLCAGM
Ceiba Investments LtdEGM re issue of shares at 104.3p each
STV Group PLCGM re bonus issue
Friday 4 December 
VinaCapital Vietnam Opportunity Fund LtdAGM
Auctus Growth PLCGM re purchase of HeiQ Materials AG
KKV Secured Loan Fund LtdEGM re investment policy, cash return, wind-down
Associated British Foods PLCAGM
Abcam PLCAGM
Hammerson PLCGM re scrip dividend
Warehouse REIT PLCGM re Greenstone acquisition
Monday 7 December 
Gore Street Energy Storage Fund PLCGM re placing programme
Renalytix AI PLCAGM
Inspecs Group PLCGM re share placing
Gabelli Value Plus+ Trust PLCGM re continuation resolution
McCarthy & Stone PLCGM re acquisition by Bidco
Tuesday 8 December 
Worsley Investors LtdAGM
Gattaca PLCAGM
Volta Finance LtdAGM
Allergy Therapeutics PLCAGM
Greatland Gold PLCAGM
Haydale Graphene Industries PLCAGM
Henderson International Income Trust PLCAGM
  
Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
26 Oct 2020 13:37

Allergy Therapeutics screens first patients in grass pollen study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the screening of the first patient in its exploratory field study 'G309', to evaluate the efficacy and safety of 'Grass MATA MPL' in subjects with seasonal allergic rhinitis or rhinoconjunctivitis induced by grass pollen exposure.

Read more
23 Sep 2020 14:02

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

Read more
4 Sep 2020 19:39

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

Read more
3 Sep 2020 15:31

Allergy Therapeutics signs new vaccine deal with Saliba and DeepVax

(Sharecast News) - Biotechnology company Allergy Therapeutics announced further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field on Thursday.

Read more
15 Jul 2020 11:47

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

Read more
15 Jul 2020 09:03

Allergy Therapeutics revenues grow despite Covid-19 disruption

(Sharecast News) - Biotechnology company Allergy Therapeutics reported a "strong" full-year performance on Wednesday despite challenges stemming from the Covid-19 pandemic.

Read more
9 Jul 2020 21:19

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

Read more
9 Jul 2020 16:26

Allergy Therapeutics pleased with invalidation of B301 trial data

(Sharecast News) - Biotechnology company Allergy Therapeutics announced the outcome of scientific advice from the German Regulatory Authority, the Paul Ehrlich Institute (PEI), over invalidation of the primary endpoint data of the Birch MATA MPL pivotal phase 3 clinical trial, or 'B301', on Thursday.

Read more
24 Jun 2020 11:53

Allergy Therapeutics Anticipates Profit Ahead Of Expectations

Allergy Therapeutics Anticipates Profit Ahead Of Expectations

Read more
24 Jun 2020 10:12

Allergy Therapeutics on track to 'significantly' exceed FY expectations

(Sharecast News) - Biotechnology company Allergy Therapeutics said on Wednesday that its 2020 trading performance was on track to exceed market expectations.

Read more
4 Mar 2020 10:46

Allergy Therapeutics Well-Placed Despite Regulatory "Challenge"

Allergy Therapeutics Well-Placed Despite Regulatory "Challenge"

Read more
26 Feb 2020 16:15

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
16 Jan 2020 13:28

Allergy Therapeutics Outlook Confident As Revenue Rises In First Half

Allergy Therapeutics Outlook Confident As Revenue Rises In First Half

Read more
26 Nov 2019 14:15

Allergy Therapeutics to take 'stepwise approach' to upcoming grass study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market on its grass MATA MPL phase 3 study, due to start in autumn 2020, on Tuesday, reporting that following further investigation of the phase 3 birch MATA MPL study, the upcoming grass study would now take a 'stepwise approach'.

Read more
25 Sep 2019 11:26

Allergy Therapeutics Looking To Chinese Market As It Swings To Profit

Allergy Therapeutics Looking To Chinese Market As It Swings To Profit

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.